Xiamen Drug Patent Portfolio
Xiamen owns 1 orange book drug protected by 2 US patents Given below is the list of Xiamen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11701352 | Process for preparing aripiprazole oral soluble film | 15 Dec, 2041 | Active |
| US11331315 | Aripiprazole oral soluble film | 03 Nov, 2040 | Active |
Latest Legal Activities on Xiamen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Xiamen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 May, 2025 | US11331315 |
| Patent Issue Date Used in PTA Calculation | 18 Jul, 2023 | US11701352 |
| Mail Patent eGrant Notification | 18 Jul, 2023 | US11701352 |
| Recordation of Patent Grant Mailed | 18 Jul, 2023 | US11701352 |
| Email Notification | 18 Jul, 2023 | US11701352 |
| Patent eGrant Notification | 18 Jul, 2023 | US11701352 |
| Electronic Review | 18 Jul, 2023 | US11701352 |
| Recordation of Patent eGrant | 18 Jul, 2023 | US11701352 |
| Electronic Review | 07 Jul, 2023 | US11701352 |
| Email Notification | 07 Jul, 2023 | US11701352 |
| Issue Notification Mailed | 06 Jul, 2023 | US11701352 |
| Email Notification | 29 Jun, 2023 | US11701352 |
| Electronic Review | 29 Jun, 2023 | US11701352 |
| Issue Notification Mailed | 28 Jun, 2023 | US11701352 |
| Dispatch to FDC | 07 Jun, 2023 | US11701352 |
Xiamen's Family Patents
Clinical Trials
Recent Clinical Trials by Xiamen:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | The First Affiliated Hospital of Xiamen University | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | The First Affiliated Hospital of Xiamen University | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) | Zhongshan Hospital (Xiamen), Fudan University | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE1 |
Xiamen Drug List
Given below is the complete list of Xiamen's drugs and the patents protecting them.
1. Opipza
Opipza is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11701352 | Process for preparing aripiprazole oral soluble film |
15 Dec, 2041
(15 years from now)
| Active |
| US11331315 | Aripiprazole oral soluble film |
03 Nov, 2040
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opipza's drug page